PFM Health Sciences’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-4,600,847
Closed -$123M 131
2018
Q3
$123M Sell
4,600,847
-478,923
-9% -$15.6M 1.8% 11
2018
Q2
$192M Sell
5,079,770
-246,901
-5% -$9.44M 3% 4
2018
Q1
$174M Sell
5,326,671
-614,384
-10% -$27M 3.53% 3
2017
Q4
$289M Buy
5,941,055
+862,909
+17% +$43.6M 6.86% 1
2017
Q3
$274M Buy
5,078,146
+2,332,304
+85% +$137M 5.39% 2
2017
Q2
$154M Buy
2,745,842
+1,053,332
+62% +$42.2M 4.15% 2
2017
Q1
$66.3M Buy
1,692,510
+1,114,360
+193% +$35.5M 1.66% 21
2016
Q4
$13M Buy
+578,150
New +$11.3M 0.37% 71

Other funds holding PTLA

PFM Health Sciences's PTLA Position: Q4 2018 in Review

PFM Health Sciences sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 4,600,847 shares — an estimated $123M sold.

PFM Health Sciences first reported a position in PTLA in Q4 2016 and held it in 8 quarters. The position peaked at $289M in Q4 2017. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • PFM Health Sciences reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • PFM Health Sciences sold 4,600,847 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $123M.
  • PFM Health Sciences first reported a position in Portola Pharmaceuticals, Inc. in Q4 2016 and held it in 8 quarters.
  • PFM Health Sciences's Portola Pharmaceuticals, Inc. position peaked at $289M in Q4 2017.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on PFM Health Sciences's 13F filing for Q4 2018, filed 14 Feb 2019.